Cellectar Biosc (CLRB) Stock Price, Quote & News

Latest News on CLRB

Jan 12, 2025, 6:00 PM EST - 7 days ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Dec 11, 2024, 11:25 AM EST - 5 weeks ago

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Dec 10, 2024, 5:00 PM EST - 5 weeks ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Nov 21, 2024, 8:00 AM EST - 2 months ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 18, 2024, 10:59 AM EST - 2 months ago

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 7:05 AM EST - 2 months ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 14, 2024, 8:05 AM EST - 2 months ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 12, 2024, 8:05 AM EST - 2 months ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 11, 2024, 4:05 PM EST - 2 months ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 7, 2024, 6:40 AM EST - 2 months ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 1, 2024, 5:00 PM EDT - 2 months ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Aug 26, 2024, 6:40 AM EDT - 5 months ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 23, 2024, 5:00 PM EDT - 5 months ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 13, 2024, 1:25 PM EDT - 5 months ago

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 6:40 AM EDT - 5 months ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 8, 2024, 5:15 PM EDT - 5 months ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Jul 24, 2024, 3:22 PM EDT - 6 months ago

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Jul 23, 2024, 3:09 PM EDT - 6 months ago

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Jul 23, 2024, 10:49 AM EDT - 6 months ago

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Jul 23, 2024, 6:40 AM EDT - 6 months ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 22, 2024, 6:40 AM EDT - 6 months ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Jun 27, 2024, 6:40 AM EDT - 7 months ago

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

May 29, 2024, 6:40 AM EDT - 8 months ago

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

May 20, 2024, 1:02 PM EDT - 8 months ago

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

May 14, 2024, 1:05 PM EDT - 8 months ago

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:40 AM EDT - 8 months ago

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

May 8, 2024, 6:40 AM EDT - 9 months ago

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

May 7, 2024, 6:40 AM EDT - 9 months ago

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

Mar 27, 2024, 12:27 PM EDT - 10 months ago

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 6:40 AM EDT - 10 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Mar 20, 2024, 6:40 AM EDT - 10 months ago

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

Mar 14, 2024, 8:52 AM EDT - 11 months ago

Cellectar Biosciences to Present at the 36th Annual Roth Conference

Mar 4, 2024, 6:40 AM EST - 11 months ago

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Feb 12, 2024, 1:34 AM EST - 1 year ago

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 7, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 30, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

Jan 25, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

$Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient$

Jan 22, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient

Jan 16, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

Jan 12, 2024, 6:44 AM EST - 1 year ago

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D.

Jan 11, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Jan 8, 2024, 6:41 AM EST - 1 year ago

Cellectar's blood cancer therapy succeeds in trial

Jan 8, 2024, 6:30 AM EST - 1 year ago

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Dec 19, 2023, 8:30 AM EST - 1 year ago

Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation

Dec 12, 2023, 8:30 AM EST - 1 year ago

Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform

Dec 5, 2023, 8:30 AM EST - 1 year ago

Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe

Nov 2, 2023, 2:19 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 7:30 AM EDT - 1 year ago

Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024

Oct 2, 2023, 6:35 AM EDT - 1 year ago

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

Sep 18, 2023, 8:40 AM EDT - 1 year ago

Market Cap	10.05M
Revenue (ttm)	0.00
Net Income (ttm)	-37.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	960,300
Avg Vol	2,928,410
Day's Range	N/A - N/A
Shares Out	41.27M
Stochastic %K	10%
Beta	1.04
Analysts	Strong Sell
Price Target	$2.00